Overview

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

Status:
Active, not recruiting

Trial end date:
2025-11-21

Target enrollment:

Participant gender:

Summary

A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease

Phase:

Phase 3

Details

Lead Sponsor:

Idorsia Pharmaceuticals Ltd.